Compared to Estimates, Nordson (NDSN) Q2 Earnings: A Look at Key Metrics

Nordson (NDSN) reported Q2 revenue of $682.94 million, a 5% year-over-year increase and a 1.39% surprise over estimates, with EPS of $2.42, up from $2.34 and 2.54% above estimates. While Advanced Technology Solutions and Medical and Fluid Solutions saw strong sales growth of 40.6% and 20% respectively, Industrial Precision Solutions sales declined by 13.1%. The stock has underperformed the S&P 500 over the past month, and carries a Zacks Rank #3 (Hold), suggesting market-average performance in the near term.

Analysis

Nordson (NDSN) reported Q2 2025 earnings with total revenue of $682.94 million, a 5% year-over-year increase, and an EPS of $2.42, surpassing analyst consensus by 1.39% and 2.54% respectively. Despite these headline beats, segment performance was mixed: the Advanced Technology Solutions division was a standout, with net sales surging 40.6% year-over-year to $161.28 million, significantly above analyst estimates of $142.32 million, and its operating profit also beat expectations at $31.56 million. The Medical and Fluid Solutions segment also demonstrated strong top-line growth of 20% to $202.81 million, narrowly missing sales estimates but exceeding operating profit estimates. However, the Industrial Precision Solutions segment, a significant contributor to revenue, posted a notable 13.1% year-over-year decline in net sales to $318.85 million, falling short of analyst projections of $322.96 million, and its operating profit of $95.72 million also missed estimates of $108.47 million. This underperformance in a key division likely contributed to the stock's recent +4.9% return, which lagged the Zacks S&P 500 composite's +7.4% gain over the past month, and aligns with its current Zacks Rank #3 (Hold) status, suggesting expectations of in-line market performance in the near term.

Key Decisions for Investors

• Investors should closely monitor the performance and any turnaround initiatives within the Industrial Precision Solutions segment, as its 13.1% year-over-year sales decline and missed profit estimates represent a significant headwind.
• The strong growth in Advanced Technology Solutions (40.6% YoY sales increase) and Medical and Fluid Solutions (20% YoY sales increase) should be evaluated for its potential to offset weaknesses elsewhere and drive future earnings.
• Given the mixed segmental results, the stock's recent underperformance relative to the S&P 500, and the Zacks Rank #3 (Hold), maintaining a neutral position while awaiting further clarity on the Industrial Precision segment's trajectory may be advisable.